Jones Financial Companies
ESPR

Jones Financial Companies’s Esperion Therapeutics ESPR Stock Holding History

Jones Financial Companies’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.81K Sell
1,202
-2,134,539
-100% -$5.97M ﹤0.01% 4222
2026
Q1 		$5.85M Buy
2,135,741
+41,329
+2% +$131K ﹤0.01% 1023
2025
Q4 		$7.75M Buy
2,094,412
+2,093,164
+167,721% +$6.76M ﹤0.01% 511
2025
Q3 		$3.31K Hold
1,248
– – ﹤0.01% 3525
2025
Q2 		$1.24K Buy
1,248
+1,175
+1,610% +$1.18K ﹤0.01% 3604
2025
Q1 		$110 Buy
+73
New +$135 ﹤0.01% 3620

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Jones Financial Companies's ESPR Position: Q2 2026 in Review

Jones Financial Companies reduced its Esperion Therapeutics (ESPR) stake by 100% in Q2 2026, selling an estimated $5.97M and leaving 1,202 shares worth $3.81K. The position accounts for ﹤0.01% of the portfolio, ranked #4222.

Jones Financial Companies first reported a position in ESPR in Q1 2025 and has held it in 6 quarters since. The position peaked at $7.75M in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Jones Financial Companies held 1,202 shares of Esperion Therapeutics worth $3.81K as of Q2 2026.
  • Jones Financial Companies sold 2,134,539 Esperion Therapeutics shares in Q2 2026, an estimated $5.97M.
  • Esperion Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4222 holding.
  • Jones Financial Companies first reported a position in Esperion Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Jones Financial Companies's Esperion Therapeutics position peaked at $7.75M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.